Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DWP14012 Tablet A vs B in Healthy Volunteers
NCT04003441Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexuprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area under the drug concentration-time curve from time 0 to tau and Peak concentration. Status: unknown.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04003441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003441.